特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カテニンベータ1:パイプライン製品の分析

Catenin Beta 1 - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 398834
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
カテニンベータ1:パイプライン製品の分析 Catenin Beta 1 - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 69 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、カテニンベータ1を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

カテニンベータ1 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Dicerna Pharmaceuticals, Inc.
  • Marina Biotech, Inc.
  • Propanc Health Group Corp
  • Warp Drive Bio, Inc.

薬剤プロファイル

休止中のプロジェクト

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Aileron Therapeutics Inc, H1 2020
  • Pipeline by Boston Biomedical Inc, H1 2020
  • Pipeline by Circle Pharma Inc, H1 2020
  • Pipeline by Dicerna Pharmaceuticals Inc, H1 2020
  • Pipeline by Fog Pharmaceuticals Inc, H1 2020
  • Pipeline by iBeCa Therapeutics, H1 2020
  • Pipeline by MD2 Biosciences Inc, H1 2020
  • Pipeline by PRISM Pharma Co Ltd, H1 2020
  • Pipeline by Propanc Biopharma Inc, H1 2020
  • Pipeline by Sapience Therapeutics Inc, H1 2020
  • Pipeline by Venn Therapeutics LLC, H1 2020
  • Pipeline by WntRx Pharmaceuticals Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC2415TDB

Summary:

Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or B-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 5 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Gastrointestinal, Non Malignant Disorders and Respiratory which include indications Colorectal Cancer, Solid Tumor, Melanoma, Hepatocellular Carcinoma, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Blood Cancer, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Head And Neck Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Idiopathic Pulmonary Fibrosis, Leukemia, Liver Cirrhosis, Lung Cancer, Myelodysplastic Syndrome, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.

Furthermore, this report also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
  • The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
    • Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
    • Aileron Therapeutics Inc
    • Boston Biomedical Inc
    • Circle Pharma Inc
    • Dicerna Pharmaceuticals Inc
    • Fog Pharmaceuticals Inc
    • iBeCa Therapeutics
    • MD2 Biosciences Inc
    • PRISM Pharma Co Ltd
    • Propanc Biopharma Inc
    • Sapience Therapeutics Inc
    • Venn Therapeutics LLC
    • WntRx Pharmaceuticals Inc
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
    • Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BBI-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exisulind - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides for Hepatoblastoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRI-724 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Beta Catenin for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Hematological and Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
  • Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer